US4767718A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Fluorescent opioid reagents and methods of use thereof in the detection of opioid receptors
Assignee: MEYERS VERA KOLB
•
Filing: 1984-06-18
•
Granted: 1988-08-30
•
Expires: 2004-06-18
Abstract
Abstract Fluorescent reagents useful as opioid receptor probes. Opioids labeled at the 3 position with fluorescers are useful in various in vivo and in vitro methods for the detection and quantification of receptor sites in tissue cells and subcellular particles.
Inventors
- 👤 Vera K. Meyers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 08:19
CPC Classifications
C; C07; C07D; C07D491/00; C07D491/02; C07D491/08; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/531; G01N33/532; G01N33/533; G01N33/94; G01N33/9486; Y; Y10; Y10S; Y10S436/00; Y10S436/80; Y10S436/815; Y10S436/816
Claims Analysis
Total Claims: 41
Claim 1
Independent Claim
73 words
A fluorescent reagent useful as a receptor probe in the detection and quantification of tissue, cells, and subcellular particles containing opioid receptors, said reagent corresponding to the formula: ##STR13## where Fl is a fluorescent moiety that emits visible light at a frequency different from any frequency at which light is emitted by any fluorescent moiety endogenous to human brain tissue, and R is a nonpeptide opioid moiety having a morphine or morphinan structure.
Claim 2
Dependent Claim
73 words
A fluorescent reagent useful as a receptor probe in the detection and quantification of tissue, cells, and subcellular particles containing opioid receptors, said reagent corresponding to the formula: ##STR13## where Fl is a fluorescent moiety that emits visible light at a frequency different from any frequency at which light is emitted by any fluorescent moiety endogenous to human brain tissue, and R is a nonpeptide opioid moiety having a morphine or morphinan structure.
Claim 3
Dependent Claim
59 words
A fluorescent reagent as set forth in claim 1 wherein R corresponds to the formula: ##STR14## where R 1 is selected from the group consisting of hydrogen, alkyl, alkenyl and alicyclic substituents, R 2 is selected from the group consisting of hydrogen, alkyl and acyl, and R 3 is selected from the group consisting of hydrogen, hydroxyl and acyloxy.
Claim 4
Dependent Claim
37 words
A fluorescent reagent as set forth in claim 2 wherein the linking group between said fluorescent moiety and said opioid moiety is ##STR15## Fl is selected from the group consisting of substituted and unsubstituted fluoresceinyl and rhodaminyl.
Claim 5
Dependent Claim
13 words
A fluorescent reagent as set forth in claim 3 wherein Fl is fluoresceinyl.
Claim 6
Dependent Claim
23 words
A fluorescent reagent as set forth in claim 4 wherein R 1 is cyclopropylmethyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 7
Dependent Claim
23 words
A fluorescent reagent as set forth in claim 4 wherein R 1 is methyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 8
Dependent Claim
23 words
A fluorescent reagent as set forth in claim 4 wherein R 1 is 2-propenyl, R 2 is hydrogen and R 3 is hydroxyl.
Claim 9
Dependent Claim
13 words
A fluorescent reagent as set forth in claim 3 wherein Fl is di-131-iodofluoresceinyl.
Claim 10
Dependent Claim
13 words
A fluorescent reagent as set forth in claim 3 wherein Fl is tetramethylrhodaminyl-B-.
Claim 11
Dependent Claim
23 words
A fluorescent reagent as set forth in claim 9 wherein R 1 is 2-propenyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 12
Dependent Claim
42 words
A fluorescent reagent useful as a receptor probe in the detection and quantification of tissue, cells, and subcellular particles containing opioid receptors, said reagent corresponding to the formula: ##STR16## where R is a nonpeptide opioid moiety having a morphine or morphinan structure.
Claim 13
Dependent Claim
42 words
A fluorescent reagent useful as a receptor probe in the detection and quantification of tissue, cells, and subcellular particles containing opioid receptors, said reagent corresponding to the formula: ##STR16## where R is a nonpeptide opioid moiety having a morphine or morphinan structure.
Claim 14
Dependent Claim
59 words
A fluorescent reagent as set forth in claim 11 wherein R corresponds to the formula ##STR17## where R 1 is selected from the group consisting of hydrogen, alkyl, alkenyl, and alicyclic substituents, R 2 is selected from the group consisting of hydrogen, alkyl, and acyl, and R 3 is selected from a group consisting of hydrogen, hydroxyl and acyloxy.
Claim 15
Dependent Claim
23 words
A fluorescent reagent as set forth in claim 12 wherein R 1 is 2-propenyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 16
Dependent Claim
23 words
A fluorescent reagent as set forth in claim 12 wherein R 1 is methyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 17
Dependent Claim
23 words
A fluorescent reagent as set forth in claim 12 wherein R 1 is cyclopropylmethyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 18
Independent Claim
109 words
A method for detecting opioid receptors in a sample of tissue, cells, or subcellur particles, comprising the steps of: contacting said sample with a receptor probe reagent selected from the group consisting of fluorescent reagents corresponding to the formulae ##STR18## where Fl is a fluorescent moiety which emits visible light at a frequency different from any frequency at which visible light is emitted by any component endogenous to human brain tissue, and R is a non-peptide opioid moiety having a morphine or morphinan structure; removing unbound fluorescent reagent from said sample; and thereafter observing the sample for fluorescence inidicating bonding of said reagent to receptor sites in said sample.
Claim 19
Independent Claim
109 words
A method for detecting opioid receptors in a sample of tissue, cells, or subcellur particles, comprising the steps of: contacting said sample with a receptor probe reagent selected from the group consisting of fluorescent reagents corresponding to the formulae ##STR18## where Fl is a fluorescent moiety which emits visible light at a frequency different from any frequency at which visible light is emitted by any component endogenous to human brain tissue, and R is a non-peptide opioid moiety having a morphine or morphinan structure; removing unbound fluorescent reagent from said sample; and thereafter observing the sample for fluorescence inidicating bonding of said reagent to receptor sites in said sample.
Claim 20
Dependent Claim
33 words
A method as set forth in claim 16 wherein the receptor sites in said sample are quantified by quantitative measurement of the fluorescent emission from said sample after removal of unbound fluorescent reagent.
Claim 21
Independent Claim
107 words
A method for determining the distribution of a particular type of opioid receptor site in a tissue sample, comprising the steps of: contacting said sample with a receptor probe reagent selected from the group corresponding to the formulae: ##STR19## wherein Fl is a fluorescent moiety which emits visible light at a frequency different from any frequency at which visible light is emitted by any component endogenous to human brain tissue, and R is a non-peptide opioid moiety having a morphine or morphinan structure; and observing the fluorescent staining pattern exhibited by said sample after contacting said sample with said reagent, thereby providing an indication of said distribution.
Claim 22
Independent Claim
107 words
A method for determining the distribution of a particular type of opioid receptor site in a tissue sample, comprising the steps of: contacting said sample with a receptor probe reagent selected from the group corresponding to the formulae: ##STR19## wherein Fl is a fluorescent moiety which emits visible light at a frequency different from any frequency at which visible light is emitted by any component endogenous to human brain tissue, and R is a non-peptide opioid moiety having a morphine or morphinan structure; and observing the fluorescent staining pattern exhibited by said sample after contacting said sample with said reagent, thereby providing an indication of said distribution.
Claim 23
Dependent Claim
63 words
A method as set forth in claim 18 wherein, in formulae I, IA and III, R corresponds to the formula ##STR20## wherein R 1 is selected from a group consisting of hydrogen, alkyl, alkenyl, and alicyclic, R 2 is selected from the group consisting of hydrogen, alkyl, and acyl, and R 3 is selected from a group consisting of hydrogen, hydroxyl and acyloxy.
Claim 24
Dependent Claim
18 words
A method as set forth in claim 19 wherein said fluorescent reagent corresponds to formula I or IA.
Claim 25
Dependent Claim
37 words
A method as set forth in claim 20 where the linking group between said fluorescent moiety and said opioid moiety is ##STR21## and Fl is selected from a group consisting of substituted and unsubstituted fluoresceinyl and rhodaminyl.
Claim 26
Dependent Claim
25 words
A method as set forth in claim 21 wherein F1 is fluoresceinyl, R 1 is cyclopropylmethyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 27
Dependent Claim
25 words
A method as set forth in claim 21 wherein F1 is fluoresceinyl, R 1 is methyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 28
Dependent Claim
25 words
A method as set forth in claim 21 wherein F1 is fluoresceinyl, R 1 is 2-propenyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 29
Dependent Claim
25 words
A method as set forth in claim 21 wherein F1 is tetramethylrhodaminyl-B-, R 1 is 2-propenyl, R 2 is hydrogen and R 3 is hydroxyl.
Claim 30
Dependent Claim
49 words
A method as set forth in claim 18 wherein said staining pattern is compared with the staining pattern obtained upon contacting a standard tissue specimen with said reagent, said standard specimen having a staining pattern associated with a known histochemical characteristic, thereby determining a histochemical characteristic of said sample.
Claim 31
Dependent Claim
48 words
A method as set forth in claim 26 wherein said staining pattern of said sample is compared with staining patterns of a set of known staining patterns, each pattern of said set being associated with a known histochemical characteristic, whereby a histochemical characteristics of said sample is determined.
Claim 32
Independent Claim
152 words
A method for detecting a neurological disorder, addiction, tolerance or pathological condition of a patient by in vitro analysis of a tissue sample taken from an organ of said patient, the method comprising contacting said sample with a receptor probe reagent selected from the group consisting of fluorescent reagents corresponding to the formulae ##STR22## wherein Fl is a fluorescent moiety which emits visible light at a frequency different from any frequency at which visible light is emitted by any component endogenous to human brain tissue, and R is a nonpeptide opioid moiety having a morphine or morphinan structure; observing the fluorescent staining pattern exhibited by said sample after contacting said sample with said reagent; and comparing said staining pattern with the staining pattern obtained upon contacting a standard tissue specimen with said reagent, said standard specimen having a staining pattern associated with a known neurological disorder, addiction, tolerance, or other pathological condition.
Claim 33
Independent Claim
152 words
A method for detecting a neurological disorder, addiction, tolerance or pathological condition of a patient by in vitro analysis of a tissue sample taken from an organ of said patient, the method comprising contacting said sample with a receptor probe reagent selected from the group consisting of fluorescent reagents corresponding to the formulae ##STR22## wherein Fl is a fluorescent moiety which emits visible light at a frequency different from any frequency at which visible light is emitted by any component endogenous to human brain tissue, and R is a nonpeptide opioid moiety having a morphine or morphinan structure; observing the fluorescent staining pattern exhibited by said sample after contacting said sample with said reagent; and comparing said staining pattern with the staining pattern obtained upon contacting a standard tissue specimen with said reagent, said standard specimen having a staining pattern associated with a known neurological disorder, addiction, tolerance, or other pathological condition.
Claim 34
Dependent Claim
63 words
A method as set forth in claim 28 wherein, in formulae I, IA and III, R corresponds to the formula ##STR23## wherein R 1 is selected from a group consisting of hydrogen, alkyl, alkenyl, and alicyclic, R 2 is selected from the group consisting of hydrogen, alkyl, and acyl, and R 3 is selected from a group consisting of hydrogen, hydroxyl and acyloxy.
Claim 35
Dependent Claim
18 words
A method as set forth in claim 29 wherein said fluorescent reagent corresponds to formula I or IA.
Claim 36
Dependent Claim
37 words
A method as set forth in claim 30 where the linking group between said fluorescent moiety and said opioid moiety is ##STR24## and Fl is selected from a group consisting of substituted and unsubstituted fluoresceinyl and rhodaminyl.
Claim 37
Dependent Claim
25 words
A method as set forth in claim 31 wherein Fl is fluoresceinyl, R 1 is cyclopropylmethyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 38
Dependent Claim
25 words
A method as set forth in claim 31 wherein Fl is fluoresceinyl, R 1 is methyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 39
Dependent Claim
25 words
A method as set forth in claim 31 wherein Fl is fluoresceinyl, R 1 is 2-propenyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 40
Dependent Claim
25 words
A method as set forth in claim 31 wherein Fl is tetramethylrhodaminyl-B-, R 1 is 2-propenyl, R 2 is hydrogen, and R 3 is hydroxyl.
Claim 41
Dependent Claim
45 words
A method as set forth in claim 28 wherein said staining pattern of said sample is compared with staining patterns of a set of known staining patterns, each pattern of said set being associated with a known neurological disorder, addiction, tolerance or other pathological condition.
References Cited (Backward Citations)
US4213904A
Cited
US4608376A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-30 | 1992-02-29 | 1992-08-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-30 | 1996-02-29 | 1996-08-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-30 | 2000-02-29 | 2000-08-30 | $7700.00 | Window Closed / Lapsed |